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Background: Malignant mesothelioma (MM) carries a poor prognosis and response rates to palliative
chemotherapy remain low. Identifying patients with MM that are unlikely to respond to chemotherapy could
prevent futile treatments and improve patient quality of life. Studies have suggested that soluble mesothelin is a
potential biomarker for early diagnosis and prognosis of MM. We set out to explore the utility of serum mesothelin
in routine clinical practice.
Methods: We conducted a prospective exploratory study of serum mesothelin levels in 53 consecutive patients
with MM at our institution between April 2009 and February 2011. Survival was assessed and analysed by
mesothelin level as both continuous and categorical variables using Cox regression models. Differences in response
rate between treatment groups were assessed by the Kruskal-Wallis Test.
Results: All 53 patients, who had been given study information agreed to participate. The patients’ median
age was 69 (range 24–90). Median mesothelin level was 2.7 nM and this value was used to dichotomize
categories: ≤2.7 nM (low) and >2.7 nM (high). The progression free survival (PFS) for low vs high mesothelin
was 8.0 vs 5.1 months (HR 1.8, p-0.058). When mesothelin was accessed as a continuous variable for PFS the
HR was 1.03 (95% CI: 1.01 - 1.06; p = 0.013). The overall survival (OS) for low vs high mesothelin was 17.2 vs 11.3 months
(HR 1.9, p = 0.088). When mesothelin was assessed as a continuous variable for OS the HR was 1.02 (95% CI: 0.99 - 1.04;
p = 0.073). Thirty patients received chemotherapy of which 18 had a pre-chemotherapy serum mesothelin level. In
these 18 patients, the pre-chemotherapy mesothelin level did not correlate with response.
Conclusions: A single random sample provides information about patient prognosis but does not predict treatment
response. We suggest further prospective validation of mesothelin testing as a prognostic biomarker.
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Malignant mesothelioma (MM) is an aggressive cancer
of serosal surfaces such as the pleura, peritoneum and
rarely the pericardium. It is causally linked to asbestos
exposure with a lag time of 15–60 years and has an inci-
dence of approximately 2500 cases/year in the UK [1].
Diagnosis of MM is challenging as symptoms and early
radiographic signs are often non-specific and their sig-
nificance can be masked by multiple co-morbidities of* Correspondence: Sanjay.Popat@rmh.nhs.uk
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unless otherwise stated.this normally older patient. Typically, histological fea-
tures of MM include positive immunohistochemical
staining for epithelial membrane antigen, WT1, cytoker-
atin 5/6 and HBME-1 [2]. Expression of several proteins
detected by immunochemistry have been suggested to
correlate with survival such as IL4Rα [3], c-MET [4],
aquaporin1 [5], calretinin [6], and HtrA1 [7]. The opti-
mal surgical approach is debated and includes palliative
support with or without chemotherapy contingent on
co-morbidities.
The identification of a robust serological biomarker
for mesothelioma could have a significant impact in thistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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invasive procedures, providing prognostic and/or predict-
ive information and aid in treatment response assessment.
The latter is particularly important, since the response
evaluation criteria in sold tumours (RECIST) and the
modified RECIST criteria for mesothelioma are associated
with significant variability [8,9]. Several candidates have
shown promise as predictive/prognostic biomarkers such
as LDH [10], C-Reactive Protein (CRP) levels (≥1 mg/dL,
predicting a poorer outcome) [11], neutrophil/lymphocyte
ratio [6], platelet count (>400,000/microL, predicting a
poorer outcome) [12], osteopontin [13], and fibulin-3 [14].
However, the most extensively studied is mesothelin,
which has been shown to potentially differentiate between
mesothelioma and other conditions, both benign and
malignant [2,15-17], and also potentially correlates
with response to therapy [18]. Mesothelin is a 40 kDa
membrane-localised protein that along with the 31 kDa
megakaryocyte potentiation factor (MPF) are cleavage
products of a 69 kDa precursor protein encoded byMSLN
on chromosome 16. Mesothelin is proposed to play a role
in cell adhesion as it binds to the cell adhesion molecule
Ca125 (Muc16) and forced over-expression of MSLN in
NIH3T3 cells leads to increased adhesion to a plastic sub-
strate. In tissue culture, mesothelin also promotes ERK
dependent proliferation [19], apoptosis resistance, anoikis
resistance and invasion [20]. Mesothelin may therefore be
involved in cancer metastasis and its role as a potential
therapeutic target is being actively pursued [21]. It is pre-
dominantly expressed in epithelioid subtype mesothelio-
mas, with little/no expression in sarcomatoid sub-types.
MPF and mesothelin isoforms 1 and 3 can be detected as
soluble proteins in plasma or serum, which may be de-
tected using a validated commercial dual antibody ELISA
platform [16]. Mesothelin level seems to correlate with
MM disease bulk and can potentially predict relapse in pa-
tients who had previously resected mesothelioma [22].
Additionally, several studies have provided some evidence
for an association between high mesothelin level and
poorer survival [13,15,23]. While the absolute baseline
serum mesothelin level has not been reported to predict
for treatment response a number of trials have demon-
strated that a fall in the mesothelin level with treatment
correlates well with radiological response rate and overall
survival [24,25].
We therefore conducted this exploratory study of serum
mesothelin testing in patients with MM in routine clinical
practice.
Methods
The study was designed and submitted as a Service
Evaluation. As such it fell under the remit of the Royal
Marsden Hospital’s Audit Committee, which approved it
without the need for a separate ethics committee approval.Patients
We identified patients attending our Cancer Centre with a
histologically confirmed diagnosis of malignant mesothelioma.
Mesothelin assay
The serum mesothelin assay was performed in a single la-
boratory. Serum samples were prospectively collected in
prevalent MM cases alongside clinical data, contemporan-
eous to on-going patient treatment and follow-up. Levels
of serum mesothelin (referred to hereafter as mesothelin)
were assayed with a commercial ELISA kit (Mesomark™
Fujirebio Diagnostics, Malvern PA) according to the man-
ufacturer’s instructions. Results were expressed in nano-
moles per litre (nmol/L). This commercially available kit
has passed FDA (US Food and Drug Administration)
quality assurance standards. All analyses were performed
in a batch, blinded to clinical outcomes.
Treatments
Patients were treated as per local standard of care. Surgery
for mesothelioma (e.g. radical pleurectomy or extrapleural
pneumonectomy) was not routine practice at the time of
this study. Patients that received chemotherapy were of-
fered treatment as per the standard institutional guide-
lines that included research protocols. At the time of this
study treatment regimens included cisplatin/pemetrexed,
cisplatin/bortezomib, mitomycin/vinblastine/cisplatin and
cisplatin/raltitrexed. To be eligible for anti-cancer systemic
therapy, patients were required to have an Eastern Co-
operative Oncology Group (ECOG) performance status ≤2
(as per local policy), have adequate renal function (clear-
ance >60 ml/min), normal haematological indices and no
serious co-morbidities, as per local guidelines. Patients
underwent pre-treatment physical examination and com-
puted tomography (CT) scan of the thorax and abdomen,
as per routine clinical care.
Response
Response was evaluated radiologically. CT scans of
the thorax and abdomen were performed at baseline
and following every 2 cycles of chemotherapy, as per
local policy. Objective radiological response was assessed
according to RECIST criteria [9]. The overall response
rate (ORR) was calculated as the proportion of patients
achieving a complete remission (CR) or partial remis-
sion (PR).
Statistics
For the purposes of this study the progression free survival
(PFS) was calculated from date of mesothelin measure-
ment to disease progression or death, otherwise censored
at the last follow-up date. Overall survival (OS) was calcu-
lated from the date of mesothelin measurement to death,
or else censored at the last follow-up date. Survival curves
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Figure 1 Scatter plot of mesothelin level of study participants.
Table 1 Patient characteristics
Variable Categories Number of
patients (%)*
Patients in study 53 (100)
Mesothelioma subtype Epitheloid 46 (87)
Sarcomatoid 1 (2)
Biphasic 5 (9)
Unknown 1 (2)
Sex Male 36 (68)
Female 17 (32)
Age Mean 69 (range 24–90)
Performance status 0 4 (8)
1 28 (53)
2 6 (11)
3 2 (4)
Unknown 13 (25)
Chemotherapy lines
including current
0 14 (26)
1 36 (68)
2 2 (4)
3 1 (2)
Chemotherapy status
while on the study
Given 30 (56.6)
Mesomark
prior to CT
12 (40)
Mesomark
post CT
18 (60)
Not given 23 (43)
*Percentages rounded up to the nearest 1.0%; Mesomark, serum mesothelin
ELISA test; CT, chemotherapy.
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was analysed for mesothelin as both continuous and cat-
egorical variables using Cox regression models. For the
categorical assessment, the two groups were assigned
as above or below and equal to the median value.
The choice of median was made prior to analysis given
the small number of patients and the presence of outlying
measurements on both sides of the spectrum. Any differ-
ences in pre-chemotherapy mesothelin and treatment re-
sponse were assessed by Kruskal-Wallis Test and Dunn’s
multiple comparison test was performed. Outcomes
were not assessed by chemotherapy regime given the
small numbers.
Results
Patient characteristics
Between April 2009 and February 2011 53 patients with
malignant mesothelioma underwent random mesothelin
level testing. The mean age was 69 years (range 24–90
years) and over 60% of patients had an ECOG perform-
ance status of 0–1 at the time of mesothelin testing. On
histological assessment, 46 (87%) patients had epitheloid
MM, 1 (2%) patient had sarcomatoid MM, 5 patients
(9%) had biphasic MM and the subtype was unknown in
1 patient (2%). Forty-nine (92%) patients had pleural
MM and 4 (8%) patients had peritoneal mesothelioma.
There was a male predominance with 36 men and 17
women (ratio 2.1:1).
Thirty out of 53 patients received chemotherapy dur-
ing their management for MM and 18/30 patients
had their mesothelin level tested in the month prior to
starting chemotherapy. Patient characteristics are sum-
marised in Table 1.Mesothelin_mean (6.6nM)
0 60
Mesothelin result (nM)
Mesothelin_median (2.7nM)
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In the 53 patients tested for serum mesothelin the mean
level was 6.6 nM (range 0.3-102.5 nM). The value of
102.5 nM appeared to be an outlier and the median was
calculated at 2.7 nM; the median value was chosen a
priori and used for subsequent analyses (Figure 1).
Progression Free Survival (PFS)
Of the 53 patients, 46 (87%) progressed and 7 (13%) were
censored. When analysed as a continuous variable the
Hazard Ratio (HR) for mesothelin was 1.03 (95% CI:
1.01 - 1.06; p = 0.013); for each unit increase in mesothelin
the hazard of progression increased by 3%. The median
PFS was 7.0 months (95% CI: 4.7 – 9.2 months) and
the median follow-up for censored patients was 18.1 months
(Figure 2A).Figure 2 Correlation between mesothelin level and PFS and OS. (A) P
as a categorical variable. (C) OS with mesothelin as a continuous variable. (
PFS, progression free survival.When mesothelin was analysed as a categorical variable
(>2.7 nM vs ≤2.7 nM) the HR was 1.8 (95% CI: 0.9 – 3.2);
p = 0.059). This translated to a median of 8.0 months
(95% CI: 3.9 – 12.0 months) for mesothelin levels ≤
2.7 nM and a median of 5.1 months (95% CI: 2.3 -
7.8 months) for mesothelin levels >2.7 nM. The me-
dian follow-up for censored patients was 14.9 months
in the ≤2.7 (nM) group and 23.8 months in the >2.7
(nM) group (Figure 2B).
Overall Survival (OS)
Of the 53 patients assessed, 29 (55%) died and 24 (45%)
were censored. When analysed as a continuous variable
the Hazard Ratio (HR) for mesothelin was 1.02 (95% CI:
0.99 - 1.04; p = 0.073); for each unit-increase in mesothe-
lin the hazard of death increased by 2%. The medianFS with mesothelin as a continuous variable. (B) PFS with mesothelin
D) OS with mesothelin as a categorical variable. OS, overall survival;
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and the median follow-up time for censored patients
was 13.8 months (Figure 2C).
When mesothelin was analysed as a categorical variable
(>2.7 nM vs ≤2.7 nM) the HR was 1.9 (95% CI: 0.9 - 4.1);
p = 0.088). This translated to a median OS of 17.2 months
(95% CI: 8.2 - 26.2 months for mesothelin levels ≤2.7 nM
and 11.3 months (95% CI: 6.7 - 15.8 months) for mesothe-
lin levels of >2.7 nM. The median follow-up for censored
patients was 13.6 months in the ≤2.7 nM group and
13.9 months in the >2.7 nM group (Figure 2D). In
summary, high mesothelin levels were non-significantly
associated with shorter OS when assessed as both con-
tinuous and categorical variables.
Response rate
To assess if mesothelin predicts for response to treatment,
18 patients whose sample was taken prior to chemother-
apy were analysed. No patients had a complete response
(CR), 5 patients (28%) had a partial response (PR), 11 pa-
tients (61%) had stable disease (SD) and 2 patients (11%)
had progressive disease (PD). This gives an overall re-
sponse rate (CR + PR) of 28% and a disease stabilisation
rate (CR + PR + SD) of 89%. In the PD group the median
mesothelin level was 10.0 (7.1-12.9), in the PR group
8.1 (2.9-23.8) and in the SD group 2.2 (0.3-10.3). Paired
comparisons between the response groups found no
significant differences in pre-chemotherapy mesothelin
levels (Figure 3).Response
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Figure 3 Correlation between the pre-chemotherapy mesothelin
level and treatment response attained. PD, progressive disease;
SD, stable disease; PR, partial response. The means ± standard
deviation are presented. There were no significant differences
between response groups.Discussion
We report the use of serum mesothelin in the assess-
ment of patients with malignant mesothelioma in rou-
tine practice. We have demonstrated an improvement in
PFS in association with lower mesothelin levels when
assessed as a continuous variable and a non-significant
improvement in PFS with lower mesothelin levels when
assessed as a categorical variable. Lower than median
mesothelin levels were also associated with a better OS,
which did not reach statistical significance.
The high patient accrual rate and absence of technical
failures of mesothelin assessment combined with the clin-
ically meaningful outcome measures suggest that random
mesothelin is both feasible and useful for routine manage-
ment of mesothelioma patients. The mean age of pa-
tients in this study was higher than our institution historical
data of patients with MM treated with chemotherapy [26]
and from RCT data (69 years vs 63 years) [27], although
performance status was similar. Despite this older patient
population, and in some cases previous lines of chemo-
therapy, the PFS (7.0 vs 6.1 months) and OS (15.4 vs
12.8 months) were higher than trial data for first-line
chemotherapy [28]. Furthermore, it must also be noted
that our definition of PFS and OS for the purposes of this
study were defined from the time of mesothelin sampling
to progression and/or death, respectively, and therefore
potentially underestimates the true OS, PFS and differ-
ences between the studies. The improved survival in our
study compared to historical controls, likely reflects a
higher proportion of female patients (32% vs 20%) and ep-
ithelioid histology (87% compared to 67%), both of which
are recognised to carry a better prognosis [10].
The role of mesothelin as a biomarker has been exten-
sively studied over recent years. A number of groups have
used similar techniques to demonstrate a relationship be-
tween high mesothelin levels and survival (Table 2). We
have been able to confirm that these previous results are
applicable to routine clinical practice and would therefore
support the use of this test in this everyday clinical setting.
We were unable to demonstrate any correlation between
the mesothelin level and the response to chemotherapy in
the 18 patients that had a pre-chemotherapy serum
mesothelin level however this study was underpowered to
detect such a difference. Likely to be of much greater
importance is the longitudinal measurement of serum
mesothelin in patients receiving treatment. A decrease in
mesothelin level has already been demonstrated in pa-
tients with MM receiving cytotoxic chemotherapy [24,25],
and could become more significant still with the advent of
mesothelin targeted immunotherapies. Anti-mesothelin
strategies that are in early phase clinical testing include
chimeric monoclonal antibodies [29], mesothelin antibody-
drug conjugates [30], anti-mesothelin vaccines [31] and
autologous transfer of T-cells transduced with chimeric
Table 2 Studies of mesothelin as a prognostic biomarker
Reference n Males (%) Median age Receiving CT (%) ORR (%) OS (months) PFS (months)
Grigoriu et al. 2007 [13] 96 81 65 85 NR m > 3.5 = 7.0 NR
m≤ 3.5 = 19.0
P = 0.003
Cristaudo et al. 2007 [34] 107 83.2 69 NR NR m > 1 = 9.8 NR
m≤ 1 = 21.5
P < 0.001
Creaney et al. 2011 [25] 97 89 66 69 m < 1 = 20.3 NR
m > 5 = 12.5
p = 0.01
Mori et al. 2013 [35] 26 21 5 26 19.2 m < 0.469* = 26.6 NR
m > 0.469* = 10.3
p = 0.027
This study 53 68 69 57** m > 2.7 = 26 m > 2.7 = 11.3 m > 2.7 = 5.1
m≤ 2.7 = 0 m≤ 2.7 = 17.2 m ≤ 2.7 = 8.0
P = 0.059†
P = 0.088
n = number patients; ORR, overall response rate; OS, median overall survival; PFS, mean progression free survival; NR, not reported; CT, chemotherapy; m, mesothelin
level in nmol/L.
*This study used the median mesothelin index, calculated by Log2 (mesothelin level after 2 courses of chemotherapy level/mesothelin level prior to chemotherapy).
Assay specifically detected N-terminal 31 kDa fragment.
**18 patients (34%) had a pre-chemotherapy mesothelin level and are therefore included in the response analysis.
†If the PFS is analysed as a continuous variable for every unit increase the there is a HR of 1.03, p = 0.013.
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fore, that pre-treatment serum mesothelin levels will serve
as a biomarker predictive of anti-mesothelin treatment re-
sponse and that longitudinal assessment will be a measure
of treatment efficacy.
We have performed a small single institution explora-
tory study on the utility of serum mesothelin measure-
ment in routine clinical practice and the findings broadly
support the data from several previously published small
prospective studies. Future, larger prospective studies are
needed to validate the results presented here, and could
be integrated with trials of mesothelin-targeted immuno-
therapy in mesothelioma. Additionally future studies must
account for covariates, such as renal function, as subse-
quent to the design of our study, renal impairment was
shown to lead to elevated mesothelin levels, which could
reduce the accuracy of this assessment [36].
Conclusions
In summary, our data suggests that serum mesothelin
assessment is a feasible and useful test for prognostica-
tion in mesothelioma in a routine clinical setting. Single
measurements of mesothelin are however of limited
clinical benefit. We advocate the validation of mesothe-
lin testing as an adjunct to chemotherapy and immuno-
therapies in future research protocols.Consent
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